Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer
Journal
JAMA Dermatology
Journal Volume
152
Journal Issue
3
Pages
340
Date Issued
2016-03
Author(s)
Abstract
With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used to treat non-small cell lung cancer. Four major skin toxic effects with different incidences have been reported from clinical studies, including acneiform eruption (60%-94%), pruritus (16%-60%), xerosis (4%-38%), and paronychia (6%-12%). 1,2 However, a direct comparison of the incidences and severities of the 4 types of skin toxic effects for 3 different EGFR-TKIs in the same patient cohort has been lacking to date.
SDGs
Other Subjects
afatinib; erlotinib; gefitinib; afatinib; antineoplastic agent; erlotinib; gefitinib; quinazoline derivative; acne; adverse outcome; controlled study; human; incidence; Letter; major clinical study; non small cell lung cancer; outcome assessment; paronychia; priority journal; pruritus; retrospective study; skin toxicity; xerosis; Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; chemically induced; cohort analysis; comparative study; compassionate use; cross-sectional study; Drug Eruptions; ichthyosis; Lung Neoplasms; paronychia; pruritus; Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies
Publisher
American Medical Association
Type
letter